Shattuck Labs, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Austin, TX. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $1 million and a loss of $49 million (its filed statements).
Pre-revenue companyPharmaceutical PreparationsAustin, TXfilings since 20168 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 2834), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 4.8 out of ten, 8 of 9 metrics filed and 1 estimated: past 4.5 out of ten, present 5.4 out of ten, future 4.4 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 8.2 out of ten. No warning events in its filings since 2017. 82nd percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 3.0 out of ten. -31.7% a year over 7 filed years; profitable in 0 of 7. 30th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 4.1 out of ten. CrossAssetData estimate 4.1/10, confidence 35 of 100 (one part). 41st percentile among 463 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 5.6 out of ten. ROE -59%: lost 59¢ per shareholder dollar. Leverage 9%: owes 9¢ per asset dollar. 56th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 3.2 out of ten. bottom 32% of 314 in its family; net margin -4880.9%. 32nd percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 6.7 out of ten. top 33% of 315 in its family for leadership; chief executive since 2020. 67th percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 5.8 out of ten. top 42% of 272 in its family for room to expand. 58th percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 2.9 out of ten. bottom 29% of 307 in its family for growth drivers. 29th percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 5.3 out of ten. top 47% of 234 in its family for expectations against reality. 53rd percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-05 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-11 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-11 (on EDGAR). Newest filing: Form SCHEDULE 13G/A, 2026-08-14. Filings on record since 2016. Read from EDGAR 2026-10-12.
Who runs it
Schreiber, Taylor (Chief Executive Officer); Neill, Andrew R (Chief Financial Officer); Shukla, Abhinav A. (Chief Technical Officer); Pandite, Arundathy N. (Chief Medical Officer); Stout, Stephen (General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer); Deyoung, Casi (Chief Business Officer); Ashiya, Mona (director); Orbimed, Advisors Llc (director); Orbimed, Capital Gp Ix Llc (director); Orbimed, Genesis Gp Llc (director); and 11 more. 21 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.